Navigation Links
ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
Date:4/22/2009

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., April 22 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2009 are expected to be released on Wednesday, April 29, 2009 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2009 first quarter and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until May 16, 2009. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
3. ViroPharma to Present at Three November Healthcare Conferences
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
6. ViroPharma to Present at Three October Healthcare Conferences
7. ViroPharma to Present at Three September Healthcare Conferences
8. ViroPharma To Acquire Lev Pharmaceuticals
9. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
10. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
11. ViroPharma to Present at Two Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... and CARDIFF, UK (PRWEB) , ... June 23, 2017 , ... ... and Brian Lula, president of Physik Instrumente USA, have been selected as this year’s ... photonics . , The two have been invited along with other honorees to accept ...
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of the inaugural RAADfest ... the very latest developments in radical life extension. RAADfest combines cutting edge science presented ... empowerment of personal development, making it the largest most comprehensive and inclusive super longevity ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell ... years until the first data on cross-contamination of human cell lines with HeLa cells ... increasing issue in cell culture labs and is associated with dramatic consequences for research. ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... to immediately determine the adulterants which pose the most likely threat to their ... 28 of this year. , IFT's annual food expo attracts over 20,000 ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):